$WGS News
Last published 1d ago
- 1d agoWGSGeneDx to Participate in Upcoming Investor ConferencesBusiness WireGAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx to Participate in Upcoming Investor Conferences
- 3d agoWGSGeneDx Research Demonstrates Medical Actionability of Exome and Genome Sequencing Results in Large Real-World Study of More Than 300,000 PatientsBusiness WireGAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Research Demonstrates Medical Actionability of Exome and Genome Sequencing Results in Large Real-World Study of More Than 300,000 Patients
- 3d agoWGSGeneDx Holdings Corp. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 3d agoWGSGeneDx Reports Third Quarter 2026 Financial ResultsBusiness WireGAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the third quarter of 2026.
- 3d agoWGSGeneDx Third Quarter 2026 Earnings Conference Call - GENEDX HOLDINGS CORPEarnings Call TranscriptsGood day and thank you for standing by. Welcome to the GDX third quarter 2026 earnings conference call at this time. All participants are in a listen-only mode. After the speaker's presentation, we'll open up for questio
- 2w agoWGSDid GeneDx Holdings Corp. Insiders Breach their Fiduciary Duties to Shareholders?PR NewswireShareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket
- 2w agoWGSGeneDx to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026Business WireGeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will release financial results for the third quarter of 2026 after the market closes
- 3w agoWGSGeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing, Advancing Rare Disease DiagnosisBusiness WireGeneDx combines clinical expertise with a phenotype-driven approach to solve complex genetic cases and deliver answers sooner GeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the
- 3w agoWGSGeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026Business WireResearch strengthens the evidence for exome and genome sequencing as standard of care across rare disease, autism, newborn screening and beyond GeneDx, the leader in rare disease diagnosis and improving health
- 1mo agoWGSGeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026Business WireNew GUARDIAN data demonstrates strong parent participation, consistent sequencing performance across diverse ancestries and actionable insights for newborns and families Data from BRIDGES-NBS shows an expert-informed
- 1mo agoWGSGeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric CareBusiness WireNew tools make genomic testing easier from ordering through results, helping pediatricians confidently integrate genomics into routine care GeneDx, the leader in rare disease diagnosis and improving health through
- 2mo agoWGSGeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type CBusiness WireNPC GenomeComplete to identify children who might otherwise remain undiagnosed through broad NPC-specific eligibility criteria, comprehensive genomic testing and expert diagnostic support GeneDx, the leader in rare
- 2mo agoWGSGeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 HonoreeBusiness WireRecognition highlights GeneDx’s leadership in moving genomic medicine to the forefront of healthcare GeneDx, the leader in rare disease diagnosis and improving health through the power of genomic data, today
- 2mo agoWGSGeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children’sBusiness WirePublished in Genetics in Medicine, study shows broad inpatient implementation of rapid genome sequencing significantly increased diagnostic rates and reduced time to diagnosis Children experiencing faltering growth
- 3mo agoWGSCG 46TH ANNUAL GROWTH CONFERENCE - GENEDX HOLDINGS CORPEarnings Call TranscriptsWelcome to the Canaccord Security Growth Conference. I'm Kyle Mixon. I cover life science tools and diagnostics for Canaccord. Please welcome me to a fireside chat with GNDX. From the company, we have CFO Kevin Feely. GN
- 3mo agoWGSCG 46th Annual Growth Conference - GENEDX HOLDINGS CORPEarnings Call TranscriptsWelcome to the Canaccord Security Growth Conference. I'm Kyle Mixon. I cover life science tools and diagnostics for Canaccord. Please welcome me to a fireside chat with GNDX. From the company, we have CFO Kevin Feely. GN
- 3mo agoWGSGeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and EpilepsyBusiness WireNew offering integrates virtual clinicians to create a scalable channel to increase availability of GeneDx exome testing for eligible children facing specialty-care barriers GeneDx (NASDAQ:WGS), the leader in rare
- 3mo agoWGSGeneDx to Participate in Upcoming Investor ConferencesBusiness WireGeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that company management will participate in upcoming investor conferences: Canaccord
- 3mo agoWGSGeneDx Second Quarter 2026 Earnings Conference Call - GENEDX HOLDINGS CORPEarnings Call TranscriptsGood day and thank you for standing by. Welcome to the GeneDx second quarter 2026 earnings conference call. At this time all participants are in a listen-only mode. After the speaker's presentation there will be a questi
- 3mo agoWGSGeneDx Reports Second Quarter 2026 Financial ResultsBusiness WireReported second quarter 2026 revenue of $114.4 million, including $100.3 million in exome and genome revenue Reported exome and genome volume growth of 32% year-over-year Reported adjusted gross margin(1) of 70%
- 3mo agoWGSGeneDx to Report Second Quarter 2026 Financial Results on Monday, August 3, 2026Business WireGeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will release financial results for the second quarter of 2026 after the market closes
- 4mo agoADMAWGSNAVNNUAIImportant Notice to Long-Term Shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA); GeneDx Holdings Corp. (NASDAQ: WGS); Navan, Inc. (NASDAQ: NAVN); and New Era Energy & Digital, Inc. (NASDAQ: NUAI) (FKA New Era Helium (NASDAQ: NEHC)): Grabar Law Office is Investigating Claims on Your BehalfGlobeNewswirePHILADELPHIA, July 07, 2026 (GLOBE NEWSWIRE) -- ADMA BIOLOGICS, INC. (NASDAQ:ADMA): Grabar Law Office is investigating whether certain officers and directors of ADMA Biologics, Inc. (NASDAQ:ADMA) breached their
- 4mo agoWGSNAVNNUAIVRRMImportant Notice to Long-Term Shareholders of GeneDx Holdings Corp. (NASDAQ: WGS); Navan, Inc. (NASDAQ: NAVN); New Era Energy & Digital, Inc. (NASDAQ: NUAI) (FKA New Era Helium (NASDAQ: NEHC)); and Verra Mobility Corporation (NASDAQ: VRRM): Grabar Law Office is Investigating Claims on Your BehalfGlobeNewswirePHILADELPHIA, July 01, 2026 (GLOBE NEWSWIRE) -- GENEDX HOLDINGS CORP. (NASDAQ:WGS): WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ:WGS). The
- 4mo agoBMIWGSGRALNAVNImportant Notice to Long-Term Shareholders of Badger Meter, Inc. (NYSE: BMI); GeneDx Holdings Corp. (NASDAQ: WGS); GRAIL, Inc. (NASDAQ: GRAL); and Navan, Inc. (NASDAQ: NAVN): Grabar Law Office is Investigating Claims on Your BehalfGlobeNewswirePHILADELPHIA, June 29, 2026 (GLOBE NEWSWIRE) -- BADGER METER, INC. (NYSE:BMI): WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders Badger Meter, Inc. (NYSE:BMI). The
- 4mo agoBMIWGSNAVNVRRMImportant Notice to Long-Term Shareholders of Badger Meter, Inc. (NYSE: BMI); GeneDx Holdings Corp. (NASDAQ: WGS); Navan, Inc. (NASDAQ: NAVN); and Verra Mobility Corporation (NASDAQ: VRRM): Grabar Law Office is Investigating Claims on Your BehalfGlobeNewswirePHILADELPHIA, June 24, 2026 (GLOBE NEWSWIRE) -- BADGER METER, INC. (NYSE:BMI): WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders Badger Meter, Inc. (NYSE:BMI). The
- 4mo agoBMIWGSGRALVRRMNotice to Long-Term Shareholders of Badger Meter, Inc. (NYSE: BMI); GeneDx Holdings Corp. (NASDAQ: WGS); GRAIL, Inc. (NASDAQ: GRAL); and Verra Mobility Corporation (NASDAQ: VRRM): Grabar Law Office is Investigating Claims on Your BehalfGlobeNewswirePHILADELPHIA, June 22, 2026 (GLOBE NEWSWIRE) -- BADGER METER, INC. (NYSE:BMI): WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders Badger Meter, Inc. (NYSE:BMI). The investigation
- 4mo agoBMIGRALVRRMWGSAttention Long-Term Shareholders of Badger Meter, Inc. (NYSE: BMI); GeneDx Holdings Corp. (NASDAQ: WGS); GRAIL, Inc. (NASDAQ: GRAL); and Verra Mobility Corporation (NASDAQ: VRRM): Grabar Law Office is Investigating Claims on Your BehalfGlobeNewswirePHILADELPHIA, June 17, 2026 (GLOBE NEWSWIRE) -- BADGER METER, INC. (NYSE:BMI): WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders Badger Meter, Inc. (NYSE:BMI). The investigation
- 5mo agoWGSGeneDx Names Mark Gardner President to Lead Its Next Phase of Scale and GrowthBusiness WireFormer Quest Diagnostics leader joins to fuel operational and commercial executionGeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced the
- 5mo agoCALXGRALVRRMWGSImportant Notice to Long-Term Shareholders of Calix, Inc. (NYSE: CALX); GeneDx Holdings Corp. (NASDAQ: WGS); GRAIL, Inc. (NASDAQ: GRAL); and Verra Mobility Corporation (NASDAQ: VRRM): Grabar Law Office is Investigating Claims on Your BehalfGlobeNewswirePHILADELPHIA , June 16, 2026 (GLOBE NEWSWIRE) -- CALIX, INC. (NYSE:CALX): WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Calix, Inc. (NYSE:CALX). The investigation concerns
- 5mo agoWGSSueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 3, 2026 in GeneDx Holdings Corp. Lawsuit - WGSPR NewswireApril 16, 2025. May 5, 2025. July 29, 2025. October 28, 2025. February 23, 2026. May 4, 2026. Between these dates, GeneDx Holdings Corp. (NASDAQ:...
- 5mo agoBMIGRALVRRMWGSImportant Notice to Long-Term Shareholders of Badger Meter, Inc. (NYSE: BMI); GeneDx Holdings Corp. (NASDAQ: WGS); GRAIL, Inc. (NASDAQ: GRAL); and Verra Mobility Corporation (NASDAQ: VRRM): Grabar Law Office is Investigating Claims on Your BehalfGlobeNewswirePHILADELPHIA, June 09, 2026 (GLOBE NEWSWIRE) -- BADGER METER, INC. (NYSE:BMI): WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders Badger Meter, Inc. (NYSE:BMI). The investigation
- 5mo agoWGSGoldman Sachs 47th Annual Global Healthcare Conference - GENEDX HOLDINGS CORPEarnings Call TranscriptsAll right, so good morning, everyone. I'm Evie Kozlowski, the Science Tools and Diagnostics Analyst here at Goldman Sachs. I am joined here today by GeneDx CFO Kevin Feely. Thank you so much for being here. Yeah, thanks
- 5mo agoWGSGeneDx Holdings (WGS) 49% Drop Triggers Investor Scrutiny Over Disconnect From Prior Growth Narrative- HBSSPR NewswireInvestors in GeneDx Holdings Corp. (NASDAQ: WGS) saw the price of their shares tank $33.42 (-49%) on May 5, 2025 after the company announced a...
- 5mo agoWGSGeneDx Holdings (WGS) 49% Drop Triggers Investor Scrutiny Over Disconnect From Prior Growth Narrative- HBSSPR NewswireInvestors in GeneDx Holdings Corp. (NASDAQ: WGS) saw the price of their shares tank $33.42 (-49%) on May 5, 2025 after the company announced a...
- 5mo agoWGSGeneDx to Participate in the Goldman Sachs 47th Annual Global Healthcare ConferenceBusiness WireGeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that company management will participate in the Goldman Sachs 47th Annual Global
- 5mo agoWGSBarrack, Rodos & Bacine Investigates GeneDx Holdings Corp. (NASDAQ: WGS) For Possible Securities FraudGlobeNewswirePHILADELPHIA, May 20, 2026 (GLOBE NEWSWIRE) -- The law firm of Barrack, Rodos & Bacine announces that it is investigating GeneDx Holdings Corp. (NASDAQ:WGS) on behalf of shareholders who have lost money in their
- 6mo agoWGSBarrack, Rodos & Bacine Investigates GeneDx Holdings Corp. (NASDAQ: WGS) For Possible Securities FraudGlobeNewswirePHILADELPHIA, May 07, 2026 (GLOBE NEWSWIRE) -- The law firm of Barrack, Rodos & Bacine announces that it is investigating GeneDx Holdings Corp. (NASDAQ:WGS) on behalf of shareholders who have lost money in their
- 6mo agoWGSWGS: GeneDX Shares Plummet Over 45%; Investors Should Contact Block & Leviton to Potentially Recover Money Through The Firm's InvestigationGlobeNewswireBOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating GeneDX Holdings Corp. (NYSE:WGS) for potential securities law violations. Investors who have lost money in their GeneDX Holdings Corp.
- 6mo agoWGSGeneDx First Quarter 2026 Earnings Conference Call - GENEDX HOLDINGS CORPEarnings Call TranscriptsGood day, ladies and gentlemen, and thank you for standing by. Welcome to the GeneDx First Quarter 2026 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation
- 6mo agoWGSGeneDx Reports First Quarter 2026 Financial Results and Updates Full-Year OutlookBusiness WireReported total revenue of $102.3 million with 27% year-over-year growth in exome and genome revenue Reported exome and genome volume growth of 34% year-over-year Reported adjusted gross margin(1) of 69% and
- 7mo agoWGSGeneDx to Report First Quarter 2026 Financial Results on Monday, May 4, 2026Business WireGeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will release financial results for the first quarter of 2026 after the market closes
- 8mo agoWGSLandmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome TestingBusiness WireNew data shows up to 61% reduction in healthcare costs for children with neurodevelopmental disorders in the 12 months following ExomeDx™ and GenomeDx™ testing, regardless of the test result GeneDx
- 8mo agoWGSBarclays 28th Annual Global Healthcare Conference - GENEDX HOLDINGS CORPEarnings Call TranscriptsAll right. Good afternoon, everybody. I'm Luke Surgat. I cover life science tools and diagnostics here for Barclays. With me, I have Kevin Feely, CFO of GeneDx. Thanks again for making it. And it's always a pleasure to h
- 8mo agoWGSZVRAGeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type CBusiness WireProgram to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC GeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the
- 8mo agoWGSGeneDx to Present 18 Abstracts at ACMG 2026, Showcasing the Scale of GeneDx Infinity™ and Real-World Genomic LeadershipBusiness WireGeneDx showcases leadership in exome and genome quality, expanded access through non-genetics ordering, and AI-driven innovations that enhance speed, scale, and diagnostic impact GeneDx (NASDAQ:WGS), the leader in
- 8mo agoWGSTD COWEN 46TH ANNUAL HEALTH CARE CONFERENCE - GENEDX HOLDINGS CORPEarnings Call TranscriptsDan Brennan, TD County Tools and Diagnostics Analyst, day one of the 46th annual conference. Pleased to be joined here with me on the stage, the management team of GNDX. To my immediate right, we have Catherine Stoolin,
- 8mo agoWGSGeneDx to Participate in Upcoming Investor ConferencesBusiness WireGeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that company management will participate in upcoming investor conferences: TD Cowen
- 8mo agoWGSGeneDx Fourth Quarter 2025 Earnings Conference Call - GENEDX HOLDINGS CORPEarnings Call TranscriptsGood day, and thank you for standing by. Welcome to the GeneDX 4th Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a questi
- 8mo agoWGSGeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026Business WireReported fourth quarter 2025 revenues of $121.0 million with 32% year-over-year growth in exome and genome test revenue (42% excluding a one-time 2024 benefit) Accelerated exome and genome volume growth to 34%
- 9mo agoWGSTIME Names GeneDx CEO Katherine Stueland to the 2026 TIME100 Health List of the World's Most Influential Leaders in HealthBusiness WireRecognition highlights growing global impact of rare disease diagnosis and the role of genomics in transforming health outcomes GeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through